The South & Central America sepsis diagnostics market is expected to grow from US$ 38.66 million in 2021 to US$ 69.59 million by 2028. It is estimated to record a CAGR of 8.8% from 2021 to 2028.

High Incidence of Sepsis due to Increasing Nosocomial Infections Fuels South & Central America Sepsis Diagnostics Market Growth

Infection is the root cause of sepsis. Sepsis mainly occurs in immunocompromised people, such as those taking chemotherapy, having a splenectomy, and suffering from AIDS and chronic illnesses like diabetes. Among several types of infections, nosocomial infections are the primary cause of morbidity and mortality among hospitalized patients. Most deaths can be prevented through early diagnosis and appropriate clinical management. These deaths are often a consequence of diarrheal diseases or lower respiratory infections. Thus, the high incidence rate of sepsis is expected to boost the demand for sepsis diagnostic products, thereby supporting the South & Central America sepsis diagnostics market growth during the forecast period.

South & Central America Sepsis Diagnostics Market Overview

The South & Central America sepsis diagnostics market is segmented into Argentina, Brazil, and the Rest of South & Central America. The market growth in the region is attributed to the rising aging population and increasing burden of sepsis cases in the region.

South & Central America Sepsis Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

South & Central America Sepsis Diagnostics Market Segmentation

The South & Central America sepsis diagnostics market is segmented on the basis of product, technology, method, test type, pathogen, end user, and country.

Based on product, the South & Central America sepsis diagnostics market is segmented into instruments, reagents and assays, blood culture media, and software. The blood culture media segment held the largest market share in 2021.

Based on technology, the South & Central America sepsis diagnostics market is segmented into molecular diagnostics, flow cytometry, microfluidics, immunoassay, biomarkers, and microbiology. The microbiology segment held the largest market share in 2021. The market for the molecular diagnostics segment is sub segmented into polymerase chain reaction, peptide nucleic acid-fluorescent in situ hybridization, syndromic panel-based testing, and microarrays.

Based on method, the South & Central America sepsis diagnostics market is bifurcated into automated diagnostics and conventional diagnostics. The conventional diagnostics segment held a larger market share in 2021.

Based on test type, the South & Central America sepsis diagnostics market is bifurcated into point-of-care tests and laboratory tests. The laboratory tests segment held a larger market share in 2021.

Based on pathogen, the South & Central America sepsis diagnostics market is segmented into bacterial sepsis, fungal sepsis, and others. The bacterial sepsis segment held the largest market share in 2021.

Based on end user, the South & Central America sepsis diagnostics market is segmented into hospitals, pathology and reference laboratories, and others. The hospitals segment held the largest market share in 2021.

Based on country, the South & Central America sepsis diagnostics market is segmented into Brazil, Argentina, and the Rest of South & Central America. Brazil dominated the market share in 2021.

Abbott; BD; bioMerieux SA; Danaher (Beckman Coulter); F. HOFFMANN-LA ROCHE LTD.; and THERMO FISHER SCIENTIFIC INC. are among the leading companies operating in the South & Central America sepsis diagnostics market.